107P Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Metastatic non-clear cell renal cell carcinoma (mnccRCC) currently lacks standard first-line treatment options. This study evaluated the effectiveness and safety of ICI plus tyrosine kinase inhibitor (TKI) in mnccRCC patients through multi-center real-world evidence, encompassing the largest sample size to date.
Authors
- Fangjian Zhou (ORCID: https://orcid.org/0000-0001-6581-8151)
- Mingqiang Chen (ORCID: https://orcid.org/0000-0002-1607-8780)
- Jing Huang (ORCID: https://orcid.org/0000-0001-9820-7648)
- Zheng Zhang (ORCID: https://orcid.org/0000-0002-5561-7601)
- Peng Dong (ORCID: https://orcid.org/0000-0002-8998-2260)
- Yun Peng (ORCID: https://orcid.org/0000-0003-4992-4370)
- Taile Jing (ORCID: https://orcid.org/0000-0002-0294-5652)
Institutions
- Central South University (CN)
- Sun Yat-sen University (CN)
- Renji Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Xiangya Hospital Central South University (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100850
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00